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Molecular Dynamics of the Dengue Virus NS3/NS2B Protease in Presence
of Inhibitor or Substrate
Maria Carolina P. Lima, Gustavo de Miranda Seabra.
Dept. Quı´mica Fundamental, UFPE, Recife, Brazil.
Dengue is a neglected tropical disease affecting millions of people, and may lead
to death. Brazil is the country with the highest number of dengue and dengue
hemorrhagic fever (D/DHF) cases combined.[1] However, recent news show
that dengue virus reaches areas that had not been hit earlier as the Madeira Island
(Portugal) [2], Florida (United States) [3], and in New Caledonia (Oceania) [4].
There are no specific medicines for the treatment of D/DHF and, once infected,
the WHO recommendations are limited to observation and symptomatic treat-
ment. Recent efforts have revealed a series of proteins essential to the dengue
virus’s life cycle, which may be used as targets for new medicines. [5].
The objective of this study is to understand the mechanism of action of the
nonstructural protein NS3 protease complexed with the cofactor NS2b (NS3/
NS2b), responsible for cleaving the viral polyprotein during the virus replica-
tion step, and understanding of interaction of this protein with its substrate and
inhibitor through molecular dynamics study.
We will be present molecular dynamics simulations of the NS3/NS2b complex
alone, in the presence of the substrate (Ala-Gly-Arg-Lys-Ser-Ile) or an inhibitor
(Bzo-Nle-Lys-Arg-Arg-H) in the active site, as well as hybrid QM/MM simu-
lations for understanding the enzymatic mechanism.
1. World Health Organization. Drug for Neglected Diseases Initiative, 2009.
http://www.dndi.org/. [06/23/2009];
2. http://www.who.int/ith/updates/20121012/en/ [12/10/2012]
3. http://edition.cnn.com/2013/08/27/health/florida-dengue/index.html [27/08/
2013]
4. http://newcaledoniatoday.wordpress.com/2013/04/06/150-contract-dengue-
fever-a-day-in-new-caledonia/ [06/04/2013]
5. Paul Erbel, Nikolaus Schiering, Allan D’Arcy, Martin Renatus, Markus
Kroemer, Siew Pheng Lim, Zheng Yin, Thomas H. Keller, Subhash G.
Vasudevan, and Ulrich Hommel, Nat. Struct. Mol. Biol. 13, 372-373.
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Dynamical Network in HIV-1 Protease and its Mutants: Implications on
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Drugs targeting HIV protease have long been used in AIDS therapy. However,
emergence of multi-drug resistance, due to active and non-active site mutations,
intensifies the need to understand the drug resistance mechanism of the enzyme.
Here, we employ molecular dynamics (MD) simulations and network analyses
to unravel the drug resistance mechanisms. Results from MD simulations sug-
gest that the mutants modulate either the ligand binding envelop in the active
site or the dynamics of flaps in HIV-1 protease.While themutations at the active
site or flap region account for drug resistance directly, the mechanism of allo-
steric mutations could not be explained. Network analyses show that the allo-
steric mutations affect the functional sites by modulating the stress centrality.
Stress interference data ascribe the residues 71, 90 and 93 as the active site mod-
ulators and 15, 20 and 36 as the flap modulators. The integrity of the global
network, however, was not affected by deletion of the mutant-prone nodes, indi-
cating that the function of HIV-1 protease is preserved.
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Understanding the Molecular Mechanism of Synergistic Inhibition in the
Hepatitis C Virus (HCV) Polymerase Using Molecular Dynamics Simula-
tions and Free Energy Calculations
Jodian A. Brown, Ian F. Thorpe.
University of Maryland Baltimore County, Baltimore, MD, USA.
The Hepatitis C Virus (HCV) affects close to 200 million globally. A major
challenge in treating this infection is the emergence of resistance to current
treatment regimens. An approach to reducing the rate of drug resistance is to
increase the inhibitory effects of allosteric inhibitors by using them in combi-
nation to target the HCV polymerase (NS5B). Although recent biochemical
studies show the use of multiple allosteric inhibitors has a synergistic inhibitory
effect on NS5B, the molecular mechanisms by which this synergistic inhibition
occurs still have not been clearly elucidated. To garner insight into the
mechanism of synergistic inhibition of NS5B, we employ conventional and
temperature accelerated molecular dynamics simulations of the enzyme simul-
taneously bound to two allosteric ligands. In concert with covariance and prin-
cipal component analyses, data from the simulations allow us to comparespecific structural and dynamic properties of the free and ligand-bound protein.
Results thus far suggest that different allosteric ligands induce distinct protein
conformations. Furthermore, when two ligands are present we observe that one
inhibitor has a dominant impact in determining protein conformation. We have
also carried out free energy calculations to understand differences in binding
free energy that arise when one or both inhibitors are bound to NS5B. Under-
standing the molecular mechanism that mediate synergistic inhibition in NS5B
may allow us to optimize the inhibitory activity of these compounds against the
enzyme. In addition, these studies can provide fundamental insights into how
ligand binding regulates protein function. Such information has direct applica-
tions in the areas of drug discovery, regulation of metabolic pathways and other
signal transduction processes.
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Hepatitis C virus (HCV) chronically infects close to 3% of the world’s popula-
tion, with 30% of carriers expected to develop serious liver-related diseases,
including hepatocellular carcinoma. There is an ongoing effort to develop novel
antivirals to improve the therapeutic outcome of anti-HCV treatment.
We explore the mechanism of action of nonnucleotide inhibitors (NNIs) of
HCV replication that bind to the thumb site II pocket on NS5B polymerase,
exemplified by GS-9669 which is in phase II clinical trials. Despite a wealth
of enzymatic and structural information regarding NS5B it is not fully under-
stood how binding at this remote pocket inhibits the active site. Stabilization
of the closed, inactive enzyme conformation has been suggested, although it
has not been described on the mechanistic level.
We employed a combination of enzyme activity, direct binding, and calori-
metric studies with GS-9669 and other classes of NNIs and several truncation
mutants of NS5B that disrupt critical interactions at the interface of the thumb
domain, b-loop and C-terminus. Our studies demonstrated unique binding and
inhibition profiles for each NNIs. An intact interface between the b-loop and
the C-terminus is critical for inhibitory potency of thumb site II NNIs, although
both elements are dispensable for binding. In addition, calorimetric studies re-
vealed the pivotal role of both regulatory elements in communication between
polymerase domains. We postulate that binding at the thumb site II pocket
locks the entire NS5B in an enzymatically inactive, closed conformation.
This stabilization of the closed conformation is a consequence of the commu-
nication between the binding pocket on the thumb domain and other domains of
polymerase that is mediated by the interactions between two key regulatory
elements: the b-loop and the C-terminal tail.
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Of the plethora of computational methods for the estimation of binding free en-
ergies, molecular dynamics based alchemical approaches provide remarkable
accuracy at an affordable computational cost. The computationally less expen-
sive empirical ligand and structure based methods require training a predictive
model to yield accurate free energy estimates. In the current study we utilized a
combinatorial chemistry library and combined the chemoinformatic and
alchemical approaches to optimize a set of known thrombin inhibitors. A
confirmed ligand scaffold (D-Phe-Pro) was selected as a basis for modifica-
tions. Prior to designing new compounds, we verified the non-equilibrium
alchemical free energy calculation setup on a set of inhibitors with experimen-
tally measured binding affinities. Afterwards, a combinatorial chemistry library
was constructed by modifying substituents at the ortho, meta and para positions
on a benzene ring facing the S1 thrombin pocket. Navigation in the library was
guided by training the Partial Least Squares based regression models using to-
pological, structural, physicochemical descriptors and COMFA-like coordi-
nates of the molecular electrostatic surfaces. The predicted potential binders
were subjected to the alchemical free energy calculations, and, subsequently,
the obtained estimates were used to update the regression models and improve
prediction accuracy. Few iterations sufficed to reach convergence towards
stronger binders, several of which were predicted to have a higher binding af-
finity than the strongest inhibitors in the initial compound set. While the newly
identified ligands are to be validated in an ITC experiment, the computational
workflow utilizing chemoinformatic approaches for navigation in a
